Current rheumatological uses of intravenous immunoglobulin.

REFERENCES 1. Buchbinder R, Hall S, Sambrook PN et al. Methotrexate therapy in rheumatoid arthritis; A life table review of 587 patients treated in community practice. / Rheumatol 1993,2fc639-44. 2. Segal R, Yaron M, Tartakovsky B. Methotrexate: mechanism of action. Semin Arthritis Rheum 1990-.20: 190-200. 3. Cronstein BN, Naime D, Ostad E. The anti-inflammatory mechanism of low dose methotrexate. Arthritis Rheum 1993;36(Suppl. 9):47. 4. Rau R. Methotrexate therapy in rheumatoid arthritis. Rheumatol Eur 1994^3:60-5. 5. Wilkinson SM, Smith AG, Davis MJ, Mattey DL, Dawes PT. Suspected cutaneous drug toxicity in rheumatoid arthritis—an evaluation. BrJRheumatol 1993; 32:798-803. 6. Combe B, Guttierez M, Anaya J, Sany J. Possible efficacy of hydoxychloroquine on accelerated nodulosis during methotrexate therapy for rheumatoid arthritis. / Rheumatol 1993^0:755-6. 7. Sany J, Anaya J, Canovas F et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. / Rheumatol 1993^0:1129-32. 8. Perhala RS, Wilke WS, Clough JD, Segal AM. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum 1991;34:146-52. 9. Morgan SL, Alarcon GS, Krumdieck CL. Folk acid supplementation during methotrexate therapy: It makes sense. / Rheumatol 1993;2(k929-30. 10. Al-Awadhi, Dale P, McKendry RJR. Pancytopenia associated with low dose methotrexate therapy. A regional survey. J Rheumatol 1993^20:1121-5. 11. Nissar M, Carlisle L, Amos RS. Methotrexate and sulphasalazine combination therapy in rheumatoid arthritis. BrJ Rheumatol 1994;7:651^t. 12. Barrera P, Laan FJM, van Riel PLCM, Dekhuijzen PNR, Boerbooms AMT, van de Putte LBA. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994^3:434-9. 13. Nyfors A, Jensen H. Frequency of malignant neoplasms in 248 long term methotrexate treated psoriatics. Dermatologica 1983;167:260-l. 14. Chandran G, Ahern MJ, Hall P et al. Cirrhosis in patients with rheumatoid arthritis receiving low dose methotrexate. Br J Rheumatol 1994;33:981-4. 15. Walker AM, Funch D, Dreyer NA et al. Determinants of serious liver disease among patients receiving low dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993;3fc329-35. 16. Berqvist SR, Felson DT, Freedberg KA. The cost effectiveness of liver biopsy in rheumatoid arthritis patients on methotrexate. Arthritis Rheum 1993; (Suppl.9):150. 17. Alarcon GS, Lightfoot RW, Kremer JM et al. Selective versus unselective liver biopsies in methotrexate treated rheumatoid arthritis patients. Arthritis Rheum 1993;(Suppl. 9):151. 18. Singh YN, Sharma M, Singh RJ, Kumar A, Malaviya R, Malaviya AN. Effects of methotrexate on clinical and immunological parameters in refractory rheumatoid arthritis: a prospective study. Br J Rheumatol 1991^30:73-4. 19. Kremer JM, Alarcon GS, Lightfoot RW et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994,37:316-28.